Home

Gwen A Melincoff

CIK 1614890 · last filed 2026-09-04

Gwen A Melincoff is a corporate insider who has filed 33 SEC Form 4 insider transactions across 7 companies since 2015. The most recent filing, for PLX, was dated Sep 4, 2026. Across all open-market trades the lifetime net is +$15.4K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.2M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.21M

Companies

7

Total Filings

33

Lifetime Open-Market Net

$15.4K

Filer Profile

Reported Address
C/O PROTALIX BIOTHERAPEUTICS, INC.
2 SNUNIT STREET, SCIENCE PARK
CARMIEL 2161401
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PLX Director 7,500 $2.64 $19.8K $0 5 2026-09-04
GANX Director — $1.75 — $0 5 2026-07-17
COLL Director 52,468 $22.75 $1.19M $0 5 2024-05-16
SOLENO THERAPEUTICS INC (SLNO) Delisted Director 666 $53.01 $35.3K $15.4K 7 2023-05-26
SOLENO THERAPEUTICS INC (SLNOW) Delisted Director — — — $0 2 2019-06-12
COLLEGIUM PHARMACEUTICAL, INC (ESPR) Delisted Director 6,960 $3.18 $22.1K $0 3 2019-04-29
Tobira Therapeutics, Inc. (TBRA) Delisted Director — — — $0 3 2016-01-14

Recent Filings

33 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-04 PLX Grant (A) — $0 EDGAR
2026-07-17 GANX Grant (A) — $0 EDGAR
2025-09-04 PLX Grant (A) +7,500 $0 EDGAR
2025-07-02 COLL Notice (144) −47,082 -$1.43M EDGAR
2025-06-25 GANX Grant (A) — $0 EDGAR
2024-06-28 SOLENO THERAPEUTICS INC (SLNO) Delisted Notice (144) −12,666 -$506.6K EDGAR
2024-06-26 GANX Grant (A) — $0 EDGAR
2024-05-16 COLL Grant (A) +7,693 $0 EDGAR
2023-10-03 PLX Grant (A) — $0 EDGAR
2023-06-26 GANX Grant (A) — $0 EDGAR
Showing 1–10 of 33
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.